NCT03355612View on ClinicalTrials.gov

XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

456

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

December 20, 2020

Study Completion Date

December 20, 2025

Conditions
Gastric Carcinoma
Interventions
DRUG

Apatinib

Apatinib: 500 mg, qd, po, last 180 days

DRUG

XELOX

Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER